BAJAJ BROKING

Notification
No new Notification messages
🚨 Trading Holiday 🚨
The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Synopsis:

Glenmark, Sun Pharma, and Zydus have initiated drug recalls in the US due to manufacturing non-compliance. Glenmark recalled over 25 products, Sun Pharma recalled 13,700 Gabapentin bottles, and Zydus recalled 3,144 Chlorpromazine bottles.


Leading Indian pharmaceutical companies Glenmark, Sun Pharma, and Zydus have voluntarily recalled several batches of medicines from the US market due to compliance concerns. These recalls were flagged under the latest enforcement reports issued by the US Food and Drug Administration (USFDA) and are related to deviations from Current Good Manufacturing Practice (CGMP) norms and contamination risks.

Also read: Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

GLENMARK PHARMACEUTICALS

Trade

1376.9-1.19 (-0.08 %)

Updated - 15 April 2025
1395.70day high
DAY HIGH
1369.00day low
DAY LOW
1172653
VOLUME (BSE)

Key Takeaways:

  • Glenmark Recall: Over 25 products withdrawn, including Propafenone, Solifenacin, Voriconazole, and Lacosamide tablets.

  • Sun Pharma Action: Around 13,700 bottles of Gabapentin capsules recalled due to contamination concerns.

  • Zydus Withdrawal: 3,144 bottles of Chlorpromazine tablets pulled from shelves due to presence of harmful impurities.

  • Recall Classifications: Glenmark and Zydus recalls are classified as Class II, while Sun Pharma’s is listed as Class III.

  • Recall Initiation Dates: Glenmark (March 13), Sun Pharma (March 4), Zydus (April 3), 2025.

Also read: HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

Glenmark Recall Overview

Glenmark Pharmaceuticals initiated a Class II recall of multiple products in March 2025. The action was taken due to manufacturing deviations identified by regulators. Products included in the recall list range from anti-epileptic medications to antifungals and urological drugs. These deviations, though not likely to result in severe health issues, warranted action to prevent potential reversible medical effects.

Sun Pharma Recall Details

Sun Pharmaceutical Industries Inc, through its US-based unit, initiated a Class III recall of Gabapentin capsules. Approximately 13,700 bottles were withdrawn due to cross-contamination risks. The medicine is widely used for treating epilepsy and nerve-related pain. Despite the lower recall severity, such actions highlight quality assurance lapses.

Zydus Recall Notification

Zydus Pharmaceuticals has recalled a batch of Chlorpromazine Hydrochloride Tablets after detecting levels of a harmful impurity beyond acceptable limits. These 10mg tablets are primarily prescribed for schizophrenia and mood disorders. The recall falls under Class II, indicating moderate risk.

Snapshot of Drug Recalls

Company

Product(s) Recalled

Recall Class

Reason for Recall

Units Affected

Glenmark

Propafenone, Solifenacin, Voriconazole, Lacosamide, etc.

II

CGMP Deviations

25+ Products

Sun Pharma

Gabapentin Capsules

III

Cross-Contamination Concerns

13,700 bottles

Zydus

Chlorpromazine Tablets 10mg

II

Harmful Impurity Detected

3,144 bottles

Impact on Market Sentiment

The announcements may influence investor sentiment across pharmaceutical stocks. Despite no immediate threats to patient safety, regulatory actions often reflect lapses in operational controls. Movements in Sun Pharma share price, Glenmark share price, and Zydus share price are likely to be watched closely in response to these developments.

The recalls indicate a heightened regulatory focus on product quality and manufacturing practices. While the affected batches have been identified and pulled from the market, companies may now face intensified scrutiny and potential corrective measures across facilities supplying to regulated markets.

Also read: Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text